SE542539C2 - Chimeric botulinum neurotoxin heavy chain binding domain - Google Patents

Chimeric botulinum neurotoxin heavy chain binding domain

Info

Publication number
SE542539C2
SE542539C2 SE1850213A SE1850213A SE542539C2 SE 542539 C2 SE542539 C2 SE 542539C2 SE 1850213 A SE1850213 A SE 1850213A SE 1850213 A SE1850213 A SE 1850213A SE 542539 C2 SE542539 C2 SE 542539C2
Authority
SE
Sweden
Prior art keywords
tab
bont
polypeptide
ofthe
protein
Prior art date
Application number
SE1850213A
Other languages
English (en)
Swedish (sv)
Other versions
SE1850213A1 (en
Inventor
Geoffrey Masuyer
Pål Stenmark
Original Assignee
Toxotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toxotech Ab filed Critical Toxotech Ab
Priority to SE1850213A priority Critical patent/SE542539C2/en
Priority to KR1020207024402A priority patent/KR20200127175A/ko
Priority to US16/975,308 priority patent/US20200407702A1/en
Priority to EP19707750.6A priority patent/EP3759124A1/en
Priority to RU2020131317A priority patent/RU2816855C2/ru
Priority to MYPI2020003674A priority patent/MY202690A/en
Priority to PCT/EP2019/054310 priority patent/WO2019162376A1/en
Priority to BR112020017323-1A priority patent/BR112020017323A2/pt
Priority to AU2019223130A priority patent/AU2019223130B2/en
Priority to JP2020568035A priority patent/JP7458999B2/ja
Priority to MX2020008834A priority patent/MX2020008834A/es
Priority to SG11202006730SA priority patent/SG11202006730SA/en
Priority to CN201980015353.XA priority patent/CN111819189A/zh
Priority to CA3088928A priority patent/CA3088928A1/en
Publication of SE1850213A1 publication Critical patent/SE1850213A1/en
Publication of SE542539C2 publication Critical patent/SE542539C2/en
Priority to PH12020551270A priority patent/PH12020551270A1/en
Priority to CL2020002186A priority patent/CL2020002186A1/es
Priority to IL276930A priority patent/IL276930A/en
Priority to JP2024043984A priority patent/JP2024069606A/ja
Priority to US18/615,341 priority patent/US20250034540A1/en
Priority to AU2024227611A priority patent/AU2024227611A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Birds (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE1850213A 2018-02-26 2018-02-26 Chimeric botulinum neurotoxin heavy chain binding domain SE542539C2 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
SE1850213A SE542539C2 (en) 2018-02-26 2018-02-26 Chimeric botulinum neurotoxin heavy chain binding domain
JP2020568035A JP7458999B2 (ja) 2018-02-26 2019-02-21 ボツリヌス神経毒バイオハイブリッド
CN201980015353.XA CN111819189A (zh) 2018-02-26 2019-02-21 肉毒神经毒素生物杂化体
EP19707750.6A EP3759124A1 (en) 2018-02-26 2019-02-21 Botulinum neurotoxin biohybrid
RU2020131317A RU2816855C2 (ru) 2018-02-26 2019-02-21 Биогибрид ботулинического нейротоксина
MYPI2020003674A MY202690A (en) 2018-02-26 2019-02-21 Botulinum neurotoxin biohybrid
PCT/EP2019/054310 WO2019162376A1 (en) 2018-02-26 2019-02-21 Botulinum neurotoxin biohybrid
BR112020017323-1A BR112020017323A2 (pt) 2018-02-26 2019-02-21 Bio-híbrido de neurotoxina botulínica
AU2019223130A AU2019223130B2 (en) 2018-02-26 2019-02-21 Botulinum neurotoxin biohybrid
KR1020207024402A KR20200127175A (ko) 2018-02-26 2019-02-21 보툴리눔 신경독소 바이오하이브리드
MX2020008834A MX2020008834A (es) 2018-02-26 2019-02-21 Biohibrido de neurotoxina botulinica.
SG11202006730SA SG11202006730SA (en) 2018-02-26 2019-02-21 Botulinum neurotoxin biohybrid
US16/975,308 US20200407702A1 (en) 2018-02-26 2019-02-21 Botulinum Neurotoxin Biohybrid
CA3088928A CA3088928A1 (en) 2018-02-26 2019-02-21 Botulinum neurotoxin biohybrid
PH12020551270A PH12020551270A1 (en) 2018-02-26 2020-08-18 Botulinum neurotoxin biohybrid
CL2020002186A CL2020002186A1 (es) 2018-02-26 2020-08-25 Neurotoxina botulinica biohibrida
IL276930A IL276930A (en) 2018-02-26 2020-08-25 Botulinum toxin biohybrid
JP2024043984A JP2024069606A (ja) 2018-02-26 2024-03-19 ボツリヌス神経毒バイオハイブリッド
US18/615,341 US20250034540A1 (en) 2018-02-26 2024-03-25 Botulinum neurotoxin biohybrid
AU2024227611A AU2024227611A1 (en) 2018-02-26 2024-10-24 Botulinum neurotoxin biohybrid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE1850213A SE542539C2 (en) 2018-02-26 2018-02-26 Chimeric botulinum neurotoxin heavy chain binding domain

Publications (2)

Publication Number Publication Date
SE1850213A1 SE1850213A1 (en) 2019-08-27
SE542539C2 true SE542539C2 (en) 2020-06-02

Family

ID=65576340

Family Applications (1)

Application Number Title Priority Date Filing Date
SE1850213A SE542539C2 (en) 2018-02-26 2018-02-26 Chimeric botulinum neurotoxin heavy chain binding domain

Country Status (16)

Country Link
US (2) US20200407702A1 (https=)
EP (1) EP3759124A1 (https=)
JP (2) JP7458999B2 (https=)
KR (1) KR20200127175A (https=)
CN (1) CN111819189A (https=)
AU (2) AU2019223130B2 (https=)
BR (1) BR112020017323A2 (https=)
CA (1) CA3088928A1 (https=)
CL (1) CL2020002186A1 (https=)
IL (1) IL276930A (https=)
MX (1) MX2020008834A (https=)
MY (1) MY202690A (https=)
PH (1) PH12020551270A1 (https=)
SE (1) SE542539C2 (https=)
SG (1) SG11202006730SA (https=)
WO (1) WO2019162376A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3752128B1 (de) * 2018-02-16 2025-01-15 preclinics discovery GmbH Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung
IL272002A (en) 2020-01-13 2021-07-29 The Israel Institute Of Biological Res Iibr Methods for identifying anti clostridial neurotoxin compounds
EP4093434A4 (en) * 2020-01-21 2024-06-26 Trustees of Dartmouth College Immunologically optimized botulinum toxin light chain variants
CN111675754A (zh) * 2020-05-19 2020-09-18 四川一埃科技有限公司 一种肉毒毒素蛋白晶体结构及晶体制备方法和解析方法
CN114957482B (zh) * 2021-02-26 2024-09-24 重庆誉颜制药有限公司 一种经修饰的神经毒素的单链多肽及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102219837B (zh) * 2010-05-20 2013-10-30 中国人民解放军军事医学科学院微生物流行病研究所 重组全长a型肉毒毒素突变体疫苗
SG10201606666XA (en) * 2012-05-30 2016-09-29 Harvard College Engineered Botulinum Neurotoxin
PT3274364T (pt) * 2015-03-26 2021-11-05 Harvard College Neurotoxina botulínica manipulada
TW201718627A (zh) * 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
GB201607901D0 (en) * 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
US11242515B2 (en) 2016-05-16 2022-02-08 President And Fellows Of Harvard College Method for purification and activation of botulinum neurotoxin
CN109476713A (zh) 2016-06-08 2019-03-15 儿童医学中心公司 工程改造的肉毒杆菌神经毒素

Also Published As

Publication number Publication date
CA3088928A1 (en) 2019-08-29
RU2020131317A (ru) 2022-03-29
IL276930A (en) 2020-10-29
CL2020002186A1 (es) 2020-12-28
MY202690A (en) 2024-05-15
SE1850213A1 (en) 2019-08-27
KR20200127175A (ko) 2020-11-10
CN111819189A (zh) 2020-10-23
JP7458999B2 (ja) 2024-04-01
WO2019162376A1 (en) 2019-08-29
JP2024069606A (ja) 2024-05-21
US20200407702A1 (en) 2020-12-31
AU2019223130B2 (en) 2024-07-25
AU2024227611A1 (en) 2024-11-14
JP2021514674A (ja) 2021-06-17
BR112020017323A2 (pt) 2020-12-29
AU2019223130A1 (en) 2020-09-10
SG11202006730SA (en) 2020-08-28
US20250034540A1 (en) 2025-01-30
MX2020008834A (es) 2021-01-08
EP3759124A1 (en) 2021-01-06
PH12020551270A1 (en) 2021-05-31

Similar Documents

Publication Publication Date Title
US20250034540A1 (en) Botulinum neurotoxin biohybrid
EP3481852B1 (en) A novel botulinum neurotoxin and its derivatives
AU2007226657B2 (en) Multivalent Clostridial toxins
CA2874587C (en) Engineered botulinum neurotoxin
US7811584B2 (en) Multivalent clostridial toxins
AU2007347781B2 (en) Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity
US8273865B2 (en) Multivalent clostridial toxins
EP3468985A1 (en) Engineered botulinum neurotoxins
JP2009513118A (ja) ボツリヌス神経毒ａタンパク質受容体およびその使用
Sharma et al. Cloning, expression, and purification of C-terminal quarter of the heavy chain of botulinum neurotoxin type A
RU2816855C2 (ru) Биогибрид ботулинического нейротоксина
WO2021190987A1 (en) Engineered botulinum neurotoxin serotype e
Leka Structural and functional characterization of AB toxins: diphtheria toxin and clostridial neurotoxins
HK40008476A (en) A novel botulinum neurotoxin and its derivatives
HK40008476B (en) A novel botulinum neurotoxin and its derivatives

Legal Events

Date Code Title Description
NUG Patent has lapsed